Nuo Therapeutics, Inc. (AURX)

0.8000 0.0000 (0.00%) At close: 03:13PM EDT

Nuo Therapeutics, Inc.

8285 El Rio
Suite 190
Houston, TX 77054
United States
346 396 4770
https://www.nuot.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 9

Key executives

Name	Title	Pay	Exercised	Year born
Mr. David E. Jorden CPA	CEO, CFO, Secretary & Executive Director	225k	N/A	1962
Dr. Peter Anton Clausen Ph.D.	COO & Chief Scientific Officer	225k	N/A	1966

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Nuo Therapeutics, Inc., a regenerative therapies company, develops, commercializes, and markets cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing in the United States. Its technology separates autologous blood to produce a platelet based therapy for the chronic wound care market. The company was formerly known as Cytomedix, Inc. and changed its name to Nuo Therapeutics, Inc. in November 2014. Nuo Therapeutics, Inc. was incorporated in 1998 and is based in Houston, Texas.

Corporate governance

Nuo Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.